呼吸器内科 論文(2018年)

英語論文

1: Morikawa A, Naito T, Sugiyama M, Okayama T, Aoyama T, Tanuma A, Omae K, Takahashi T. Impact of Cancer Cachexia on Hospitalization-associated Physical Inactivity in Elderly Patients with Advanced Non-small-cell Lung Cancer. Asia Pac J Oncol Nurs. 2018 ;5(4):377-382.

2: Omori S, Oyakawa T, Naito T, Takahashi T. Gefitinib-Induced Cardiomyopathy in Epidermal Growth Receptor-Mutated NSCLC. J Thorac Oncol. 2018 ;13(10)

3: Wakuda K, Kobayashi H, Omori S, Nakashima K, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Takahashi T. Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer. Jpn J Clin Oncol. 2018 ;48(9):822-826.

4: Kawamura T, Kasai H, Fermanelli V, Takahashi T, Sakata Y, Matsuoka T, Ishii M, Tanigawara Y. Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data. Cancer Sci. 2018 ;109(9):2822-2829.

5: Watanabe M, Kenmotsu H, Ko R, Wakuda K, Ono A, Imai H, Taira T, Naito T, Murakami H, Abe M, Endo M, Nakajima T, Koh Y, Takahashi T. Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. Cancer Sci. 2018 ;109(8):2539-2548.

6: Kawamura T, Murakami H, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Endo M, Takahashi T. Leptomeningeal recurrence after long- term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein. Invest New Drugs. 2019 ;37(1):184-187.

7: Omori S, Kenmotsu H, Abe M, Watanabe R, Sugino T, Kobayashi H, Nakashima K, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Ohde Y, Endo M, Akiyama Y, Nakajima T, Takahashi T. Changes in programmed death ligand 1 expression in non- small cell lung cancer patients who received anticancer treatments. Int J Clin Oncol. 2018 ;23(6):1052-1059.

8: Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small- Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy. J Cancer. 2018 ;9(11):2054-2060.

9: Oyakawa T, Muraoka N, Iida K, Kusuhara M, Kawamura T, Naito T, Takahashi T. Crizotinib-induced simultaneous multiple cardiac toxicities. Invest New Drugs. 2018 ;36(5):949-951.

10: Miyawaki E, Murakami H, Takahashi T. Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma. J Thorac Oncol. 2018 ;13(5):e79-e81.

11: Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Murakami H, Endo M, Takahashi T. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease. Lung Cancer. 2018 ;121:48-53.

12: Mamesaya N, Wakuda K, Omae K, Miyawaki E, Kotake M, Fujiwara T, Kawamura T, Kobayashi H, Nakashima K, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Mori K, Harada H, Endo M, Nakajima T, Takahashi T. Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. Oncotarget. 2018 ;9(25):17664-17674.

13: Shirasu H, Ono A, Omae K, Nakashima K, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Takahashi T. CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. Tumour Biol. 2018 ;40(2).

14: Kawamura T, Kenmotsu H, Omori S, Nakashima K, Wakuda K, Ono A, Naito T, Murakami H, Omae K, Mori K, Tanigawara Y, Nakajima T, Ohde Y, Endo M, Takahashi T. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR- Mutant Non-small-cell Lung Cancer. Clin Lung Cancer. 2018 ;19(2):e247-e252.

呼吸器内科

呼吸器内科